REPLY: Treatment with oxLDL antibody reduces cathepsin S expression in atherosclerosis via down-regulating ADAR1-mediated RNA editing

Int J Cardiol. 2017 Feb 15:229:8. doi: 10.1016/j.ijcard.2016.12.008. Epub 2016 Dec 6.

Authors

Christian Bo Poulsen¹, Ahmed Ludvigsen Al-Mashhadi², Jacob Fog Bentzon², Erling Falk²

Affiliations

¹ Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address: cbpoulsen@clin.au.dk.
² Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

PMID: 28003044
DOI: 10.1016/j.ijcard.2016.12.008

No abstract available

Publication types

Letter

MeSH terms

Adenosine Deaminase / metabolism*
Antibodies, Monoclonal / pharmacology*
Cathepsins / metabolism*
Coronary Artery Disease* / metabolism
Coronary Artery Disease* / therapy
Down-Regulation
Humans
Immunologic Factors / pharmacology
Lipoproteins, LDL* / antagonists & inhibitors
Lipoproteins, LDL* / immunology
RNA Editing / drug effects
RNA-Binding Proteins / metabolism*
Recombinant Proteins / pharmacology

Substances

Antibodies, Monoclonal
Immunologic Factors
Lipoproteins, LDL
RNA-Binding Proteins
Recombinant Proteins
oxidized low density lipoprotein
Cathepsins
cathepsin S
ADAR protein, human
Adenosine Deaminase